The basis for persistence of leukemic stem cells in the bone marrow microenvironment remains poorly understood. We present evidence that signaling cross-talk between a4 integrin and Abelson interactor-1 (Abi-1) is involved in the acquisition of an anchorage-dependent phenotype and drug resistance in Bcr-Abl-positive leukemia cells. Comparison of Abi-1 (ABI-1) and a4 integrin (ITGA4) gene expression in relapsing Bcr-Abl-positive CD34 þ progenitor cells demonstrated a reduction in Abi-1 and an increase in a4 integrin mRNA in the absence of Bcr-Abl mutations. This inverse correlation between Abi-1 and a4 integrin expression, as well as linkage to elevated phospho-Akt and phospho-Erk signaling, was confirmed in imatinib mesylate -resistant leukemic cells. These results indicate that the a4-Abi-1 signaling pathway may mediate acquisition of the drug-resistant phenotype of leukemic cells.
INTRODUCTION
Chronic myeloid leukemia (CML) originates from transformation of a hematopoietic stem cell (HSC) by the oncogenic kinase Bcr-Abl. 1 Despite the indisputable success of small-molecule inhibitors of Bcr-Abl in prolonging the survival of patients with Bcr-Abl-positive leukemia, the leukemic stem cells (LSCs) remain detectable in the bone marrow (BM). 2, 3 There are two well-documented mechanisms of Bcr-Abl resistance to tyrosine kinase inhibitor (TKI) treatment, both leading to cell autonomous activation of Bcr-Abl kinase: mutations in the catalytic domain and amplification of the oncogene. [4] [5] [6] In addition, detailed mechanistic studies of imatinib mesylate (IM) resistance and persistence of Bcr-Abl-containing HSCs have shown that primitive CML cells are capable of survival in the absence of Bcr-Abl kinase activity. 2, 7 These studies suggest the existence of a kinase activity-independent mechanism of acquired drug resistance, where primitive LSCs, which remain insensitive to the presence of TKI, are responsible for relapse after TKI discontinuation. 8, 9 In this scenario, non-catalytic, adapter functions of Bcr-Abl are thought to contribute to the oncogenic characteristics of CML stem cells, suggesting the need to identify Bcr-Abl kinase-independent mechanisms of survival of LSCs in the presence of TKI.
Interactions of HSCs with the BM microenvironment (BMME) are critical for sustaining stem cell pools. 10 The stem cell niche regulates stem cell-specific properties, including self-renewal, multi-potentiality and relative quiescence. 11 Evidence points to the involvement of the BMME in survival and systemic retention of LSCs. 12 Integrins, particularly a4b1 and aVb3, which control lodging of HSCs in the BMME and HSCs trafficking in general, are also crucial for the persistence of minimal residual disease. 13, 14 The Berlin-Frankfurt-Munster acute lymphoblastic leukemia (ALL) trial (ALL-REZ BFM 2002) revealed that high expression of a4b1 at first relapse was associated with poor molecular response to therapy and significantly worse event-free and overall survival. 15 Based on these and other reports, a concept emerged suggesting that a subpopulation of LSCs remains quiescent and exhibits relative drug resistance as a result of enhanced adhesive properties toward BM stroma. 12, 16 Abelson interactor 1 (Abi-1) was originally identified as Abl kinase-associating protein 1 17 and was later confirmed to be one of the Bcr-Abl interactors. 18 Abi-1, via the Ras small G-protein, has an essential role in the regulation of cell proliferation and, via Rac activation, can affect actin remodeling, cell adhesion and cell migration. 19, 20 Abi-1 is a vital component of WAVE2, N-WASP and Dia complexes and functions as an actin cytoskeleton organization regulator. [21] [22] [23] [24] Abi-1 also associates with various small Rho GTPase guanine exchange factors, including Eps8/Sos-1 complex, 25, 26 bPIX 27 and Vav2. 28 Recent reports indicate that the N-terminus of Abi-1 interacts with the cytoplasmic tail of a4 integrin and may mediate specific functions associated with a4-dependent processes in normal and pathological conditions. 29 Abi-1deficient mice exhibit defects in placental and cardiovascular development leading to midgestational embryonic lethality; 29, 30 these phenotypes mirror those found in mice deficient for a4 integrin or its ligand vascular cell adhesion molecule-1 (VCAM-1). 31, 32 In this report, we present data indicating that Abi-1 has a role in signaling cross-talk between Bcr-Abl and a4 integrin. Our results suggest that the a4 integrin-Abi-1-Bcr-Abl signaling module may have a significant role in interactions between LSCs and the BMME and that alterations in this cross-talk may be causative in the acquired drug-resistant phenotype of LSCs.
MATERIALS AND METHODS

Patients and donors
Human CD34 þ cells were isolated from BM mononuclear cells (AllCells, LLC, Emeryville, CA, USA) or from peripheral blood mononuclear cells (Rhode Island Blood Bank). CML CD34 þ cells were isolated from peripheral blood of CML patients either at diagnosis or at relapse. Clinical characteristics of the patients are detailed in Table 1 . Presence of Philadelphia chromosome was confirmed in all samples. Quantitative PCR and sequencing analyses confirmed T315I, F317L or E450K mutation in three of the six CML patients with recurrent disease. After initial diagnosis, these patients were subject to treatments with imatinib, which was followed by treatment with dasatinib, nilotinib, rebastinib or ponatinib. The patients currently remain on a combination of ponatinib/hydroxyurea, dasatinib/vincristine/prednisone or hydroxyurea alone. One of the patients underwent allogeneic BM transplant. No Bcr-Abl mutations were found in the remaining three (of six) CML patients with relapsing disease. These patients, after initial treatment with imatinib or dasatinib, remain on nilotinib or dasatinib. All patients provided informed consent. This study was approved by the institutional review boards at Roger Williams Medical Center, Rhode Island Hospital and Memorial Hospital of Rhode Island. Deidentified whole BM or purified CD34 þ samples accrued at CML diagnosis or at relapse were also obtained from Dr Brian Druker (Oregon Health and Science University-Knight Cancer Institute, Portland, OR, USA).
Cell lines
Ba/F3 control cells and Ba/F3 cells expressing E255K, M351T and T315I mutants of p210 Bcr-Abl were also a kind gift from Dr Druker and were established from an immortalized murine BM-derived pro-B-cell line as described. 33 IM-resistant K562-STI-S/p and K562-STI-S/s cells and the control cells (cI) were a kind gift from Dr Steven Grant, Virginia Commonwealth University, Richmond, VA, USA and were established from K562 (Bcr-Abl-positive human erythroleukemia, ATCC no. CCL-243) by subculturing the cells in progressively higher concentrations of IM. 34 K562-STI-R, K562 control cells (cII) and LAMA-84-S and -R were kindly provided by Dr Carlo Gambacorti-Passerini, University Milan Bicocca, Monza, Italy and were produced as described. 35 Control K562, human LAMA-84-S or murine Ba/F3 cells (expressing non-mutated 'wild-type' (WT) Bcr-Abl) were grown in RPMI 1640 supplemented with 2 mM GlutaMax, 50 mg/ml streptomycin, 50 IU penicillin and 10% fetal bovine serum. IM-resistant cells were grown in 0.1 mM IM (K562-STI-S/p and K562-STI-S/s) or in 0.6 mM IM (K562-STI-R, LAMA-84-R, Ba/F3 E255K , Ba/F3 M351T , Ba/F3 T315I ). For proliferation and spreading analyses, cells were grown on surfaces Isolation of CD34 þ cells CD34 þ progenitor cells were isolated from anti-coagulated blood or from BM of CML patients or healthy donors. The mononuclear fraction was isolated by Ficoll density gradient centrifugation (2500 r.p.m. Â 15 min, room temperature). The separated interphase cells were washed and optionally treated with red blood cell lysis buffer. The cell pellet was incubated with CD34 microbeads and FcR-blocking reagent. The CD34 þ fraction was separated on LS separation columns using a QuadroMACS Separator (Miltenyi Biotec Inc., San Diego, CA, USA). CD34 À cells were also collected. Cells were subjected to RNA isolation immediately or were frozen in 10% dimethyl sulfoxide, 30% fetal bovine serum, 1% GlutaMax in Iscove's Modified Dulbecco's Medium and stored at À 80 1C until use.
RESULTS
Abi-1 mRNA levels decrease in CML CD34 þ therapy-resistant cells Higher expression of a4b1 in relapsing leukemic samples has been reported. 15, 36 In view of the known interaction of Abi-1 with a4 integrin and the potential role of Abi-1 signaling in the mechanism(s) of drug resistance, we examined Abi-1 (ABI-1) and a4 integrin (ITGA4) mRNA levels in CD34 þ cells isolated from healthy controls and from CML patients at diagnosis and at first relapse. In CML CD34 þ cells, there was no significant difference in the mRNA levels of Abi-1 and nearly 30% lower mRNA levels of ITGA4 (a4 gene) in comparison with CD34 þ cells from healthy subjects (Figures 1a and b ). Comparison of Abi-1 mRNA levels in CML CD34 þ vs CML CD34 þ with Bcr-Abl mutations (CML res/mut CD34 þ ) indicated a trend towards increased levels of Abi-1 mRNA in CML res/mut CD34 þ ( Figure 1c ). No significant differences in levels of ITGA4 were noted in these cells ( Figure 1d ). When we compared CML CD34 þ and CML CD34 þ without detectable Bcr-Abl mutations (CML res/no mut CD34 þ ), we found that CML res/no mut CD34 þ cells exhibited lower Abi-1 mRNA levels and nearly twofold higher ITGA4 mRNA levels (Figures 1e and f ). An inverse correlation between ABI-1 and ITGA4 mRNA levels was noted in all three CML res/no mut CD34 þ specimens analyzed. The details of patients' diagnosis and treatment are presented in Table 1 . We have also compared the levels of expression of CD49d (a4) on the surface of CML CD34 þ vs CML res/no mut CD34 þ cells. The results indicated greater expression of CD49d on the surface of resistant cells (Figure 1g ), which correlated with higher levels of ITGA4 noted in CML res/no mut CD34 þ cells ( Figure 1f ). Altogether these findings indicated a possible role of Abi-1 and a4 integrin in the mechanisms of acquired resistance.
Abi-1 protein levels are reduced in Bcr-Abl-positive IM-resistant cells To acquire a better understanding of the mechanistic details of a4-Abi-1-Bcr-Abl cross-talk and its possible role in drug resistance, we examined CML cell lines growing in low or high concentrations of IM. IM acts as an environmental stressor, which induces resistance either via amplification of the oncogene (i), occurrence of activating mutations in the oncogene (ii) or loss of Bcr-Abl and activation of the so called 'by pass mechanism' of resistance (iii). K562-STI-S cells (p and s clones) were cultured in low concentrations of IM (0.1 mM); under these conditions, these lines displayed amplification of Bcr-Abl. In these cells, we observed increased levels of Bcr-Abl, enhancement of its phospho-Tyr412 signal, phosphorylation on Ser473 of Akt and phosphorylation of Thr220/204 of Erk 1/2 (Figure 2a ). K562-STI-R cells were grown in higher concentrations of IM (0.6 mM), which corresponds to the calculated physiological concentration of the drug in the BM during treatment. Despite a notable reduction in the levels of Bcr-Abl oncogene in K562-STI-R cells, we observed sustained phosphorylation of Tyr412 of Bcr-Abl, increased levels of phosphorylation on Ser473 of Akt and on Thr220/204 of Erk 1/2, suggesting activation of a Bcr-Abl-independent mechanism of resistance in these cells (Figure 2a ). Murine Ba/F3 pro-B cells transformed with Bcr-Abl p210 'WT' or Bcr-Abl p210 bearing clinically relevant mutations: E255K, M351T, or T315I represent a model of third type of the mechanism of resistance: occurrence of oncogene-activating mutations. These Bcr-Abl mutant-containing cell lines, despite growing in 0.6 mM IM, were insensitive to IMinduced environmental stress, because the specific mutations inhibited binding of the drug. Indeed, no significant differences in phospho-Bcr-Abl, -Akt or -Erk were observed in Ba/F3 cells ( Inhibition of ubiquitin-proteasome pathway only partially restores protein levels of Abi-1 Bcr-Abl-dependent targeting of Abi-1 by the ubiquitinproteasome pathway has been reported 37 and was shown to be associated with activation of Bcr-Abl signaling. We found that treatment of the IM-resistant cells and their non-resistant counterparts with the proteasome-ubiquitin pathway inhibitor lactacystin for 16 h induced a substantial elevation in protein levels of Abi-1 in K562-STI-S cells in comparison with control cells (Figure 2e ). No effect of lactacystin on Abi-1 protein level was observed in IM-resistant K562-STI-R cells (Figure 2e ), and as expected, no change in Abi-1 was observed in Ba/F3 cells upon lactacystin treatment ( Figure 2f ). These results suggest that, in K562-STI-S cells, amplification of Bcr-Abl may correlate with increased levels of Abi-1 mRNA; however, because Bcr-Abl had activated the ubiquitin-proteasomal pathway, Abi-1 protein levels are reduced in these cells. In K562-STI-R cells, initially low protein levels of Bcr-Abl may correlate with initially low levels of ABI-1 mRNA and be indicative of existence of epigenetic mechanism(s) regulating expression of Abi-1.
Enhanced adhesive properties are observed in IM-resistant cells Analysis of the cellular phenotype of IM-resistant cells showed that K562-STI-S cells displayed an irregular shape with irregular protrusions, whereas450% of all K562-STI-R cells became adherent (Figure 3a and Supplementary Movies S1A-E). These phenotypes contrast with parental control K562 cells, which are round and grow in suspension (Figure 3a , Supplementary Movies S1A and D). All Ba/F3 cells, including control cells, exhibited an irregular shape with protrusions, and all grew in suspension (Figure 3b , Supplementary Movies S2A-D). To analyze the effect of attachment on growth and morphology of K562-STI-R cells, we compared their growth on standard tissue culture-treated surfaces (uncharged, hydrophobic), untreated surfaces (negatively charged, hydrophilic) and ultra-low attachment surfaces (neutral, hydrophilic hydrogel coated). We have not observed any morphological changes in K562 parental cells grown on any of these surfaces, and cells were 100% removable from the culture plate with warm ; CML CD34 þ cells isolated from peripheral blood of CML patients at diagnosis (n ¼ 5); CML CD34 þ cells isolated from peripheral blood of CML patients at relapse, which had point mutations in Bcr-Abl (n ¼ 3); and CD34 þ cells isolated at relapse, which lacked point mutations in Bcr-Abl (n ¼ 3). Detailed patient information is presented in Table 1 . No significant difference in ABI-1 (a) and nearly 50% decrease in ITGA4 (b) transcript levels were observed in CML CD34 þ samples vs healthy control CD34 þ . Moderately increased levels of ABI-1 (c) and unchanged levels of ITGA4 transcripts (d) were observed in CML CD34 þ (res/mut) cells isolated at relapse. A decrease in the amount of Abi-1 mRNA levels (e) and a nearly twofold increase in ITGA4 levels (f ) were observed in CML CD34 þ cells without Bcr-Abl mutations isolated at relapse. Expression relative to actin mRNA (ACTB), expressed as fold change, is presented. Samples were run in quadruplicates; the experiment was performed three times. Primer and probe details are presented in Supplementary Tables 1 and 2 . Evaluation of the expression levels of CD49d on the surface of the CML CD34 þ cells without Bcr-Abl mutations isolated at relapse vs CML CD34 þ control samples showed an increased amount of CD49d on the surface of relapsing CD34 þ progenitor cells (g). Figures S1A and C) . K562-STI-R cells could not be removed with warm phosphatebuffered saline from treated, untreated or ultra-low attachment plates, and 70, 47 or 21% cells, respectively, remained attached to the plates upon washing with warm phosphate-buffered saline ( Supplementary Figures S1B and C) . We noticed a significant decrease in the number K562-STI-R cells grown on ultra-low attachment surfaces, suggesting that adhesion was important for optimum growth of these cells. The enhanced adhesive properties of IM-resistant cells prompted us to evaluate anchorage-dependent growth of these cells in semi-solid media. Evaluation of the total colony number in K562 cells indicated a 50% decrease in Real-time quantitative PCR analysis of ABI-1 mRNA showed a more than eightfold increase in ABI-1 transcript levels in K562-STI-S, and a 50% decrease in Abi-1 expression in K562-R cells (c). No significant differences in ABI-1 transcript levels were seen in Ba/F3 cells expressing 'WT' Bcr-Abl or its mutants (E255K, M351T or T315I) (d). Upon incubation with 2 mM lactacystin, restoration of Abi-1 protein levels was detected in K562-STI-S cells (e). No effect of lactacystin on K562-STI-R or Ba/F3 cells was noted (e, f ). Representative immunoblotting data from three independent experiments are presented.
phosphate-buffered saline (Supplementary
formation of colonies by IM-resistant K562-STI-S/p and K562-STI-S/s cells. K562-STI-R cells exhibited a nearly 98% loss of capacity to form colonies in semi-solid media, and few colonies were noted ( Supplementary Figures S2A and C) . Notably, colonies formed by K562 IM-resistant cells, especially by K562-STI-S/p and K562-STI-S/s cell lines, were larger, dense and well defined in comparison with the small and irregularly bordered colonies formed by K562 control cell lines (Supplementary Figure S2A) . Ba/F3 cells formed only one-tenth as many colonies as K562 cells, and Ba/F3 Bcr-Abl mutant cells formed nearly 50% fewer colonies than control Ba/F3 WT cells ( Supplementary Figures S2B and D) . However, the colonies formed by Ba/F3 E255K , Ba/F3 T315I and particularly Ba/F3 M351T were larger than colonies formed by the control cell line (Supplementary Figure S2B) . Overall, these results indicate that K562-STI-R IM-resistant cells acquired an anchorage-dependent growth phenotype.
IM-resistant cells exhibit significantly increased expression of a4 integrin
Emerging evidence points to the role of a4b1 integrin in adhesion-mediated drug resistance. 36, 38 The observations that Abi-1 interacts directly with the C-terminus of a4 integrin and that aberrant protein levels of Abi-1 are found in IM-resistant cells suggest that Abi-1-a4 cross-talk may be involved in the process of adhesion-mediated drug resistance. We evaluated protein levels of several integrins known to be expressed on hematopoietic cells. In K562-STI-S cells, we observed increased levels of aV and b3 integrins, as previously reported for IM-resistant cells 39 (Figure 3c) . Surprisingly, overexpression of these integrins was not observed in K562-STI-R cells. Instead, K562-STI-R cells exhibited significantly upregulated expression of a4 integrin (Figure 3c ). Closer evaluation of the expression pattern of a4 integrin in K562-STI-S cells revealed the abundant presence of its 70/80-kDa fragment (Figure 3c ). The 70/80 and 150-kDa fragments of a4 integrin are products of the same gene; the 70/80-kDa fragment is generated as a result of proteolysis. 40 Relatively modest enhancement of expression of the 150-kDa fragment of a4 integrin was observed in Ba/F3 Bcr-Abl mutant cells (Figure 3d ). Real-time PCR analyses of the ITGA4 (a4 gene) expression levels confirmed a430-fold increase in the mRNA levels of ITGA4 in K562-STI-S and -R cells (Figure 3e ). These data support the notion that expression of a4 integrin is elevated in IM-resistant K562-STI-S and -R cells. However, in K562-STI-S cells, proteolysis occurred, resulting in generation of the 70/80-kDa fragment from the 150-kDa protein, likely because of the activation of the ubiquitin-proteasome pathway (Figure 3c ). No significant differences were observed among the different Ba/F3 cell lines with respect to either a4 mRNA or protein levels (Figures 3d and f) . These results correspond with results obtained from relapsing Bcr-Abl-positive CD34 þ progenitor cells. Analysis of the extracellular expression pattern of a4 (CD49d) by fluorescence-activated cell sorter was in agreement with immunoblotting data: K562-STI-R cells exhibited significantly increased levels of CD49d expression, whereas the expression pattern of CD49d on K562-STI-S cells was comparable to expression on K562 control cells (Figure 3g ). This suggested that the 70/80-kDa fragment detected by immunoblotting does not possess the extracellular region recognized by the anti-CD49d antibody. We have not observed significant differences in the CD49d expression pattern in Ba/F3 cells (Figure 3h ). Isotype controls are presented in Supplementary Figures S3A and B . The results suggest that the higher expression levels of a4 integrin may be associated with acquired resistance to IM.
Decreased proliferation and significantly increased adhesiveness characterize IM cells cultured on VCAM-1-coated surfaces It is known that binding of integrin a4b1 to its counter receptor (VCAM-1) is essential for placental and cardiac development. a4b1-VCAM-1 binding also has a critical role in the interactions between HSCs and BM stroma and regulates tumor angiogenesis and homing of hematopoietic stem and progenitor cells. [41] [42] [43] [44] In view of the significant upregulation of a4 integrin that we observed in IM-resistant cells, we evaluated the effect of exposure of the IM-resistant cells to VCAM-1 on adhesion and proliferation. We found that the K562 control cell lines cI and cII did not adhere to VCAM-1-coated surfaces. However, 490% of K562-STI-S and -R cells were adherent to a VCAM-1-coated surface (Supplementary Movies 3A-E). Among all Ba/F3 cells, including WT control and all analyzed mutants, we observed490% adhesion to VCAM-1coated surfaces (Supplementary Movies 4A-D). When IM-resistant cells were cultured on VCAM-1-coated surfaces, growth potential was reduced. Growth of K562-STI-S/s, -R or Ba/F3 E255K or M351T cells was inhibited by 20-30%, and growth of K562-STI-S/p and Ba/F3 T315I cells was inhibited nearly 50% (Figures 4a and b) . These findings suggest that overexpression of a4 in IM-resistant cells may support quiescence of these cells and may contribute to the mechanisms of acquired drug resistance.
Expression pattern of cyclins confirms loss of proliferative potential of K562-STI-R cells cultured on VCAM-1-coated surfaces
In order to evaluate in greater detail the proliferative potential of K562-STI-R cells cultured on VCAM-1-coated surfaces, we analyzed levels of expression of cyclins A, B, E and H, cyclin-dependent kinases (cdks) 1, 2, 4 and 6 and inhibitors p18, p21 and p27 in these cells in comparison to K562 control cell line. Expression of cyclins A2, B1, D3 and H was reduced in K562-STI-R cells grown on uncoated surfaces and was further decreased in K562-STI-R cells cultured in the presence of VCAM-1 (Figures 4c and d) . Similarly, cdks 1, 4 and 6, which were expressed at low levels in K562-STI-R cells grown on uncoated surfaces, were found to be expressed at even lower levels in resistant cells in the presence of VCAM-1 (Figures 4e and f) . Expression of cdk inhibitors 1B (p27, CDKN1B) and 2C (p18, CDKN2C) was increased in K562-STI-R cells regardless of the presence or absence of VCAM-1 (Figures 4e and f) . We noted a significant upregulation of cyclins D2 and E1 in K562-STI-R cells cultured on VCAM-1-coated plastic compared with control K562 cells (Figure 4d ). The results suggested that, despite inconsistencies in the expression of cyclins, that is, decreased expression of cyclins A2, B1, D1, D3 and H (favoring G1/G0 phase of the cell cycle) and upregulation of cyclins D2 and E (favoring G1/S phase progression of the cell cycle), low levels of expression of cdks and p18, 21, and 27 inhibitors resulted in decreased proliferative potential of K562-STI-R cells grown in the presence of VCAM-1. These results were confirmed in cell cycle analysis by propidium iodide staining of K562-STI-R cells alone and grown over the VCAM-1-coated surfaces. We noted relatively modest (B10%) but statistically significant increase in the number of cells in G0/G1 phase after culture on VCAM-1-coated plastic (Figure 4g ). Stem cells markers NANOG and Sox2 were also upregulated in K562-STI-R cells ( Supplementary Figures S4A and B) . Overall, these results suggest that the decreased proliferative potential exhibited by K562-STI-R cells is likely due to acquisition of an adhesive phenotype. In the presence of ligand for a4 integrin, proliferation is further decreased.
Abi-1 associates with a4 integrin and Bcr-Abl in IM-resistant cells It was recently shown that Abi-1 associates with the cytoplasmic tail of a4 integrin. 29 To confirm Abi-1-a4 association in IM-resistant cells, we performed immunoprecipitation experiments. We found that anti-Abi-1 antibodies coimmunoprecipitated 150-kDa a4 in K562-STI-R cells, and the 70/80-kDa fragment was coimmunoprecipitated in all the analyzed K562 cell types (Supplementary Figure S5A) . We were not able to coimmunoprecipitate Bcr-Abl in K562-STI-R cells, possibly because the levels of Bcr-Abl in K562-STI-R cells were very low. The possibility that the interaction between Abi-1 and 150-kDa a4 excludes association between Abi-1 and Bcr-Abl seems unlikely, as we were able to coimmunoprecipitate 150-kDa a4 integrin and Bcr-Abl in LAMA-84 cells (Supplementary Figure S5C) . In Ba/F3 cells, we were able to immunoprecipitate the 70/80-kDa fragment but not the 150-kDa fragment of a4, likely because the 150-kDa a4 integrin is not abundant in these cells. No differences were noted between Ba/F3 control and mutant cells in the amounts of coimmunoprecipitated 70/80-kDa a4 integrin fragment (Supplementary Figure S5B) . These data confirm the association of Abi-1 with both a4 integrin and Bcr-Abl and indicate that Abi-1 may be a linker between Bcr-Abl and a4 signaling pathways.
Loss of Abi-1 affects both a4 integrin and Bcr-Abl signaling in IMresistant cells Our data suggest that Abi-1 may serve as a linker between a4 and Bcr-Abl signaling pathways, and its loss observed in IM-resistant cells may be a contributing factor to the mechanism of resistance.
To better understand the role of Abi-1 signaling in acquired resistance, we assessed the effect of Abi-1 loss on a4 and Bcr-Abl signaling pathways. Notably, in our analysis, we also included b1 signaling, as a4 forms a dimer with b1 integrin, and b1 activation is known to induce Akt/Erk signaling via activation of the first downstream effector of b1, integrin-linked kinase (ILK). 45 However, only a weak phosphorylation signal on Ser246 was detected on ILK, indicating the absence of ILK activation in IM-resistant K562 cells (Supplementary Figure S6A) . A weak phosphorylation signal on Ser294 of ILK was also observed in all Ba/F3 cells (Supplementary Figure S6B) . These results indicated that induction of Akt/Erk signaling in IM-resistant cells was not achieved via b1/ ILK, but must have been via another pathway, possibly the a4-Abi-1-Bcr-Abl axis, as we do observe enhancement of Akt/Erk activities in IM-resistant cells (Figure 2a ). We also analyzed FAK/Src/PAK/ p130Cas activities as they are known to be induced in response to a4 signaling. Surprisingly, we noted different signaling responses in cell lines growing in low vs high concentrations of IM. In K562-STI-S/p and K562-STI-S/s cells characterized by the amplification of Bcr-Abl oncogene and decreased levels of Abi-1 (Figure 2a ), we observed increases in phospho-FAK, -Src, -p130Cas and -PAK (Supplementary Figure S6C) . In contrast, in K562-STI-R cells, where both Bcr-Abl and Abi-1 levels were significantly decreased (Figure 2a ), activation of FAK/Src/p130Cas and PAK was lost (Supplementary Figure S6C) . No significant alteration in FAK/Src/ p130Cas/PAK signaling was observed in Ba/F3 cells expressing IMinsensitive Bcr-Abl mutants (Supplementary Figure S6D ). In addition, sensitivity to IM of K562-STI-S and -R cells was also indicated by decreased levels of phospho-CrkL in these cells (Supplementary Figure S6C) . Ba/F3 cells expressing Bcr-Abl mutants remained insensitive to the presence of the drug as indicated by the steady-state levels of pCrkL (Supplementary Figure S6D) . These results show that a4-Abi-1-Bcr-Abl signaling leads to activation of FAK/Src/Pak signaling in cells growing in lower concentrations of IM, whereas at higher IM concentrations, wherein Bcr-Abl and Abi-1 levels are low, signaling from the a4-Abi-1-Bcr-Abl module is lost.
Forced expression of Abi-1 results in reduced levels of integrin a4 and decreased phosphorylation of Akt and Erk1/2 Because we observed reduced expression of Abi-1 and enhanced expression of integrin a4 in K562-STI-R cells, we evaluated the effect of overexpression of Abi-1 on the levels of the integrin and the activities of Akt and Erk 1/2 kinases. As expected, overexpression of Abi-1 resulted in decreased expression of a4 integrin and phospho-Akt and -Erk signaling in both K562-STI-R and K562 control cells (Figures 5a and b ). We also evaluated the adhesive properties and the cell cycle status of K562-STI-R cells vs K562-STI-R overexpressing Abi-1 (K562-STI-R/Abi-1) cultured on the VCAM-1-coated or uncoated surfaces. In comparison with K562-STI-R cells, K562-STI-R/Abi-1 population was less adherent to VCAM-1 and showed only modest increase in their proliferative potential (Figures 5c and d) . To evaluate the effect of Abi-1 overexpression (and consequent reduction in expression of a4 integrin) on the localization of the leukemic cells to the BM, we injected K562 cells overexpressing Abi-1 (K562cI/Abi-1) into NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. We observed a decrease in the number of K562cI/Abi-1 cells populating the BM in comparison with the K562 control cells, what was assessed by morphological observations and immunoblotting (Figures 6a-c) . We also observed formation of K562-derived tumors in NSG mice injected with K562 cells overexpressing Abi-1 (Figures 6d-f ). The presence of K562 in these tumors was confirmed by fluorescence in situ hybridization (Figure 6g ). The results suggest that the loss of a4 integrin, as a consequence of Abi-1 overexpression, may result in impaired localization of K562/Abi-1 cells to the BM leading to the formation of K562-derived tumors.
DISCUSSION
The detection of Bcr-Abl expressing LSCs persisting in CML patients receiving TKI treatment, despite effective inhibition of Bcr-Abl tyrosine kinase activity, is suggestive of highly effective mechanisms of resistance that are independent of Bcr-Abl. 2,3 LSCs are exposed to TKI in the context of the BMME; therefore, it is reasonable to suspect that the microenvironment has a protective role in the systemic persistence of LSCs. 12, 46 We, and others, have begun to unravel details of these microenvironment-mediated Bcr-Abl-independent mechanisms of resistance. Numerous proteins at the LSC-microenvironmental interface control lodging and behavior of LSCs within the BM niche. Integrins, along with Notch and N-cadherin, are required for LSCs to lodge to the BM niches. 47 The attachment of AML cells to the BM stroma through interaction between a4b1 integrin on leukemic cells and fibronectin on mesenchymal stromal cells has been shown to be crucial for the persistence of minimal residual disease in AML. 13 Mudry et al. 14 showed that the maximum viability of ALL cells during exposure to cytarabine and etoposide required interaction with the mesenchymal stromal cell adhesion molecule VCAM-1, a ligand for a4b1 integrin. It was also recently shown that blockade of a4 integrin sensitizes drug-resistant pre-B ALL to chemotherapy. 36 These studies indicate a role of integrin a4b1 in the mechanisms of drug resistance; however, the molecular details of a4 involvement in this process are poorly understood. The role of Abi-1 in leukemogenesis and acquired resistance is not known, but recent confirmation of its direct interactions with a4 integrin 29 and the fact that Abi-1 is one of the major Bcr-Abl interactors 18 indicate that there may be a biological connection between these three signaling cascades.
To evaluate this possibility, we have examined expression levels of Abi-1 and a4 genes in three types of CML progenitors: CML CD34 þ cells, CML CD34 þ cells resistant to treatment because of the presence of mutations in Bcr-Abl (CML res/mut CD34 þ , insensitive to IM as environmental stressor) and CML CD34 þ cells resistant to treatment without mutations in Bcr-Abl (CML res/mut CD34 þ , sensitive to IM); healthy CD34 þ cells were used as controls. In our view, sensitivity or resistance to IM corresponds to the capacity of the drug to act as an environmental stressor. Our data indicated that Abi-1 was downregulated in relapsing CML CD34 þ progenitor cells in the absence of Bcr-Abl mutations. It is known that treatment with IM and its derivatives decreases the amount of detectable Bcr-Abl transcripts in cells lacking Bcr-Abl mutations; however, in cells containing Bcr-Abl mutations, levels of Bcr-Abl remain relatively unchanged following IM treatment. 48 If, as our data may indicate, Abi-1 mRNA and Bcr-Abl levels correlate, then the expression level of Abi-1 in CML CD34 þ resistant cells with mutated Bcr-Abl will be unchanged, but Abi-1 levels in resistant CML CD34 þ cells that carry unmutated Bcr-Abl will be lower. Indeed, we observed this trend (Figures 1c and e ). In addition, in CML CD34 þ cells that were resistant to IM treatment but carried unmutated Bcr-Abl, the observed decrease in Abi-1 mRNA was accompanied by elevated levels of a4 integrin, consistent with published reports showing a correlation between increased levels of ITGA4 and relapse. 15, 36 To evaluate the mechanistic details of a4-Abi-1-Bcr-Abl crosstalk, we have used well-defined cellular systems that were either sensitive or insensitive to IM treatment. In Bcr-Abl-containing cell lines, we confirmed that in cells in which the oncogene was amplified (K562-STI-S/p or K562-STI-S/s), we also observed an increase in Abi-1 mRNA, whereas in K562-STI-R cells, in which expression of Bcr-Abl is significantly decreased, a decrease in Abi-1 mRNA levels was seen. These results are consistent with observations made in relapsing CML CD34 þ cells. In addition, as was seen in drug-resistant CML CD34 þ cells, in both K562-STI-S and -R cells we observed an inverse correlation between mRNA transcript levels of ITGA4 and Abi-1. As levels of Abi-1 and Bcr-Abl Lower levels of Bcr-Abl were detected by immunoblotting in the BM of NSG mice injected with K562 overexpressing Abi-1 (c). In mice injected with K562/Abi-1 cells, large tumors associated with the urinary tract were noted (d, e). Only one tumor was found in mice injected with K562 control cells (f ). Presence of K562 cells in tumors was confirmed by fluorescence in situ hybridization. Objective Â 100 was used (g).
fall and a4 levels rise, adhesive properties of cells increase. Indeed, in K562-STI-R cells, we observed a dramatic change in phenotype; these cells, which typically grow in suspension, became adherent and acquired an anchorage-dependent phenotype. In vivo, this characteristic would likely result in retention of these cells in the BMME, which would affect their cell cycle status, supporting their quiescence and resulting in resistance to treatment. Consistent with this, in vitro, we observed growth inhibition of IM-resistant cells cultured on VCAM-1-coated surfaces. These observations were further confirmed in experiments in which Abi-1 was overexpressed. We found that enforced expression of Abi-1 protein resulted in decreased a4 integrin levels and diminished capability of K562 cells overexpressing Abi-1 to locate to the BM, which in turn may have led to tumor formation.
Enhanced phosphorylation of a4 integrin downstream effectors, including FAK, Src, CrkL and PAK, has been shown in K562-STI-S cells growing in low concentrations of IM. 49, 50 Phosphorylation of CrkL in this complex is Bcr-Abl dependent and is decreased owing to the presence of IM. Less phosphorylated CrkL forms a stable complex with p130 Cas and activates Rac1, which is reflected in activation of the Rac1 effector, PAK. We do not observe enhancement of phospho-FAK/Src/p130Cas/PAK in K562-STI-R cells, and levels of Bcr-Abl and Abi-1 are significantly decreased in these cells. Thus the evidence is consistent with the interpretation that, despite significant overexpression of a4 in these cells, signaling through the a4-Abi-1-Bcr-Abl axis to FAK/Src/p130Cas and PAK is lost in K562-STI-R cells. Notably, in IM-insensitive Ba/F3 cells expressing Bcr-Abl mutants, we neither observed changes in a4, Abi-1 or Bcr-Abl expression levels nor observed modulation of FAK/Src/p130Cas/PAK signaling.
Finally, we sought to identify factors that control the expression of ABI-1 in IM-resistant cells. Using a TargetScan (Release 6.2, Whitehead Institute for Biomedical Research, Cambridge, MA, USA), 51 which predicts targets of micro-RNAs (miRNAs) by screening for conserved sites matching the seed region of each miRNA, we found that 3 0 untranslated region of ABI-1, in the position 131-137, was a target for miR-181a (Figure 7a ). Affymetrix analysis performed on K562-STI-R cells showed significant upregulation of miR-181a in these cells (Figure 7b ). These results were further confirmed by quantitative PCR, which indicated a nearly fivefold upregulation of miR-181a ( Figure 7c ) in IM-resistant cells. These results further suggested that miR-181a may serve as a regulator for ABI-1 gene expression. Complete data set is presented in Supplementary Table S3 .
In summary, our results indicate that, in leukemic cells affected by IM-induced environmental pressure, the a4-Abi-1-Bcr-Abl signaling axis has a role in acquired drug resistance. We hypothesize that Abi-1 links the Bcr-Abl and a4 signaling cascades and that abnormal expression of Abi-1 may contribute to the process of acquired drug resistance. Our results also indicate that the inverse correlation between Abi-1 and a4 integrin expression may provide a useful prognostic marker of treatment outcome in relapsing Bcr-Abl-positive leukemia. 
